Baxalta Innovations GmbH
- Address
- Industriestrasse 67, Donaustadt
Sponsor Overview
Specializations
Congenital thrombotic thrombocytopenic purpura
Clinical research in cTTP focuses on ADAMTS13 replacement and the management of microvascular thrombosis linked to severe deficiency of this enzyme. The studies address both prophylactic treatment and on-demand therapy in patients with inherited thrombotic disease.
- ADAMTS13 replacement therapy
- Thrombotic microangiopathy
- Bleeding and clotting balance
The sponsor’s work in this area is centered on haematology and inherited disorders of coagulation control.
Hereditary severe von Willebrand disease in children
Research in severe von Willebrand disease addresses control of nonsurgical bleeding and support for perioperative haemostasis in paediatric patients. The therapeutic interest includes recombinant von Willebrand factor and its use in children with inherited bleeding disorders.
- Paediatric haemostasis
- Bleeding episode control
- Inherited von Willebrand disease
This area reflects a focus on paediatric haematology and the treatment of rare coagulation disorders.
Primary immunodeficiency diseases
Clinical activity in primary immunodeficiency centers on long-term support for patients with impaired immune function, with attention to immunoglobulin replacement and ongoing treatment tolerability. The research landscape includes chronic care for inherited immune defects and related infection risk.
- Immunoglobulin therapy
- Immune system deficiency
- Long-term treatment tolerability
The sponsor is active in clinical immunology and disorders marked by recurrent infections and immune dysfunction.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Long-Term Safety and Efficacy of Recombinant ADAMTS13 (rADAMTS13) in Prophylactic and On-Demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura |  Austria France Germany Italy Poland Spain | Not Recruiting |
| Evaluation of Long-term Safety and Tolerability of Human Normal Immunoglobulin and Hyaluronidase (Human Recombinant) in Primary Immunodeficiency Diseases |  Czechia Denmark Germany Greece Poland Slovakia Spain The Netherlands | Recruiting |
| Evaluation of the Efficacy and Safety of Recombinant Von Willebrand Factor with or without Octocog Alfa in Pediatric Severe Hereditary Von Willebrand Disease | Austria Belgium France Italy Spain | Not Recruiting |
Data & Insights
This sponsor works with 5 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 39 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases2 trials249 other sponsors
- 2.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
39 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Via Posillipo 226, 80123 Naples
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Boulevard Tanguy Prigent, 29200 Brest
- Address
- Avenue De La Cote De Nacre, 14000 Caen
- Address
- Jihlavska 340/20, Bohunice, 625 00 Brno
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Baxalta Innovations GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.